NCT06562023

Botulinum Toxin and Mesotherapy on Enhancement of Facial Scarring

Botulinum Toxin Versus Mesotherapy on Enhancement of Facial Scarring (A Randomized Controlled Clinical Trial)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Hams Hamed Abdelrahman · Academic / Other
• Sex: All
• Age: 20 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

Most of the body's tissues can undergo wound repair following a disruption of tissue integrity. Upon healing, these wounds result in scar formation. The scars widen when the overlying musculature pulls apart suture lines. Botulinum Toxin A (BTA) is known to prevent fibroblast proliferation and it also induces temporary muscle paralysis. Also, mesotherapy is the non-invasive transdermal injection which can aid the skin to increase collagen and elastin production. Thus, both techniques are eligible for enhancement of facial scars.

Conditions

• Facial Scars

Interventions

Type	Name	Description
OTHER	Botulinum Toxin Type A	Patients will receive BTA injection within a period of 5 days after primary closure.
OTHER	Mesotherapy	Patients will receive mesotherapy growth factor serum with a derma pen within a period of 5 days after primary closure.

Timeline

• Start date: 2022-11-19
• Primary completion: 2024-07-20
• Completion: 2024-07-20
• First posted: 2024-08-20
• Last updated: 2024-08-20

Locations

1 site across 1 country: Egypt